News Conference News EACTS 2024 In-Hospital Mortality Higher When Female CABG Patients Have Male Surgeons Yael L. Maxwell October 14, 2024
News Conference News EACTS 2024 MACE in CV Trials: Has the Outcome Outlived Its Role? Yael L. Maxwell October 11, 2024
News Conference News EACTS 2024 Will Semaglutide Change Cardiac Surgery? It Already Has Yael L. Maxwell October 10, 2024
News Conference News ESC 2024 ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions Michael O'Riordan September 17, 2024
News Daily News Burden of CVD Still High in UK Despite Prevention Efforts Over 20 Years Yael L. Maxwell June 26, 2024
News Conference News NY Valves 2024 National Data Point to Soaring TAVI Rates in Patients Under 65 Michael O'Riordan June 14, 2024
News Opinion Off Script The Future of Cardiothoracic Surgery, Too, Lies in Innovation Friedhelm Beyersdorf, MD May 13, 2024
News Daily News Certain Periprocedural MIs Don’t Matter, New Data Allege Michael O'Riordan May 09, 2024
News Conference News ACC 2024 Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6 Yael L. Maxwell April 08, 2024
News Daily News Intravascular Imaging Lowers Risk of MACE at 1 Year in Left Main PCI Michael O'Riordan March 26, 2024
News Daily News M-TEER Outcomes at 1 Year Best at Hospitals With High Mitral Surgical Volumes Michael O'Riordan March 15, 2024
News Conference News STS 2024 CT Surgery Needs Universal Policies for Pregnancy and Family Leave, Survey Shows Yael L. Maxwell February 07, 2024
News Conference News STS 2024 TAVI, SAVR Almost Equally Performed in California Patients Under 60 Yael L. Maxwell February 01, 2024
News Conference News STS 2024 STS Survey Identifies Stark Gender Disparities in Compensation Yael L. Maxwell January 30, 2024
News Daily News Socioeconomics Mire Access to All AVR Options for Aortic Stenosis Yael L. Maxwell January 22, 2024
News Features Going Solo: Can TAVI Be Performed Without a Surgical Safety Net? Michael O'Riordan January 22, 2024
News Conference News TCT 2023 Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials Michael O'Riordan October 24, 2023